Regulatory RNAs and Cancer Section, Genetics Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
RNA Biol. 2021 Dec;18(12):2097-2106. doi: 10.1080/15476286.2021.1899500. Epub 2021 Mar 26.
Long noncoding RNAs (lncRNAs) are an increasing focus of investigation due to their implications in diverse biological processes and disease. Nevertheless, the majority of lncRNAs are low in abundance and poorly conserved, posing challenges to functional studies. The CRISPR/Cas system, an innovative technology that has emerged over the last decade, can be utilized to further understand lncRNA function. The system targets specific DNA and/or RNA sequences via a guide RNA (gRNA) and Cas nuclease complex. We and others have utilized this technology in various applications such as lncRNA knockout, knockdown, overexpression, and imaging. In this review, we summarize how the CRISPR/Cas technology provides new tools to investigate the roles and therapeutic implications of lncRNAs.
长链非编码 RNA（lncRNAs）因其在多种生物过程和疾病中的作用而成为研究热点。然而，大多数 lncRNAs 丰度低且保守性差，这给功能研究带来了挑战。CRISPR/Cas 系统是过去十年中出现的一项创新技术，可以用于进一步了解 lncRNA 的功能。该系统通过向导 RNA（gRNA）和 Cas 核酸酶复合物靶向特定的 DNA 和/或 RNA 序列。我们和其他人已经将这项技术应用于多种应用，如 lncRNA 敲除、敲低、过表达和成像。在这篇综述中，我们总结了 CRISPR/Cas 技术如何为研究 lncRNAs 的作用和治疗意义提供新工具。
